Final answer:
Heather Bresch, as the former CEO of Mylan, faced significant risks such as EpiPen pricing scandals and regulatory pressures. Post her leadership role, her risks may revolve around the impact on her reputation and professional career following her tenure.
Step-by-step explanation:
The question pertains to assessing the risks associated with Heather Bresch, the former CEO of Mylan, a pharmaceutical company. As of my knowledge cutoff in 2023, Heather Bresch faced several risks while she was CEO, such as pricing scandals, especially around the EpiPen, intense competition in the pharmaceutical industry, and regulatory pressures. However, considering she stepped down after Mylan's merger with Upjohn to form Viatris in 2020, her current risks could be different, potentially regarding her professional reputation and any residual effects from her time at Mylan.
It is important when discussing corporate leadership to consider the broad variety of risks that a CEO might encounter. These include, but are not limited to, regulatory scrutiny, issues with product pricing, and challenges to company reputation. Leaders must navigate these waters carefully to safeguard both their own professional standing and the health of the enterprise they manage.